fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

CHMP positive recommendation for Ixchiq a Chikungunya vaccine – Valneva SE

Written by | 4 Jun 2024

Valneva SE a specialty vaccine company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion… read more.

The surprising power of a century-old vaccine for tuberculosis

Written by | 9 Apr 2024

Scientists in Canada believe they may be closer to understanding a positive additional benefit associated with Bacillus Calmette Guérin (BCG), a century-old vaccine for tuberculosis. It turns out… read more.

Just ask: patients in the ER are willing to get a flu shot

Written by | 29 Mar 2024

Simply asking patients to get the flu vaccine, and combining it with helpful video and print messages, is enough to persuade many who visit emergency departments to roll… read more.

Improving public understanding of the vaccine adverse event reporting system

Written by | 28 Feb 2024

The Vaccine Adverse Event Reporting System (VAERS) is an open, national surveillance system used by medical professionals as well as the public at large to self-report potential adverse… read more.

Vaccination before Covid-19 infection significantly reduces risk of long covid

Written by | 25 Nov 2023

Covid-19 vaccination prior to infection significantly reduces the risk of developing post-covid-condition (PCC), commonly known as long covid, researchers reported on Nov. 22, 2023 in The BMJ/British Medical… read more.

Health Canada authorization for XBB.1.5-adapted monovalent COVID-19 vaccine – Pfizer + BioNtech SE

Written by | 6 Oct 2023

Pfizer Canada ULC and BioNTech SE announced that Health Canada has authorized the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (Comirnaty Omicron XBB.1.5) for ages 6 months and older…. read more.

Pharmacists can improve access to life-saving vaccines

Written by | 3 Oct 2023

HPV, or human papillomavirus, is the most common sexually transmitted infection. It is also the leading cause of cervical cancer. Over 1,400 Canadian women are affected yearly, with… read more.

Elderly patients receiving high-quality primary care are more likely to receive varicella-zoster virus vaccination on doctor’s recommendation

Written by | 24 Sep 2023

Aging has been identified as a significant risk factor for herpes zoster, a skin disease caused by the same virus that causes chickenpox. With the aging of the… read more.

First RSV vaccine to protect infants and older adults

Written by | 7 Sep 2023

EU medicines regulators have approved a vaccine to protect against disease caused by the respiratory syncytial virus (RSV). Abrysvo is the first RSV vaccine indicated for passive immunisation… read more.

Autumn COVID-19 vaccines to target XBB variant

Written by | 19 Jun 2023

Vaccines against COVID-19, administered in the EU in the autumn of 2023, will be updated to target XBB forms of the SARS-CoV-2 virus. These strains are a subgroup… read more.

Previous smallpox vaccine provides immunity to mpox

Written by | 26 May 2023

Vaccines against smallpox given until the mid-1970s offer continuing cross-reactive immunity to mpox (previously known as monkeypox), researchers from Karolinska Institutet in Sweden report in a study published… read more.

Community health van increases access to a vaccine that helps to prevent six types of cancer

Written by | 6 May 2023

In a joint initiative that includes Hollings Cancer Center and the Department of Pediatrics, MUSC researchers launched a community mobile health van in 2021 to help to increase… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.